The current place and indications of 131I-metaiodobenzylguanidine therapy in the era of peptide receptor radionuclide therapy: determinants to consider for evolving the best practice and envisioning a personalized approach.

Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role? South Asian J Cancer (2017) 0.75

'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs. Nucl Med Commun (2011) 0.88

Bronchoalveolar carcinoma of lung masquerading as iodine avid metastasis in a patient with minimally invasive follicular carcinoma of thyroid. Clin Nucl Med (2008) 0.82

Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol. Eur J Nucl Med Mol Imaging (2014) 0.82

Detection by (18)F-FDG PET of unsuspected extensive bone marrow metastases in a case of basosquamous carcinoma of the cheek. Hell J Nucl Med (2011) 0.82

Adding surgery as a complementary approach to radioiodine therapy in patients of differentiated thyroid carcinoma with large solitary flat bone metastases: the unresolved issues. J Surg Oncol (2011) 0.78

Advantages of surgical extirpation in addition to radioiodine therapy in differentiated thyroid carcinoma patients with a solitary large-volume skeletal metastasis with small-volume oligometastatic disease in the rest of the whole body. J Cancer Res Ther (2013) 0.77

The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study. Nucl Med Commun (2016) 0.76

Asymptomatic myocardial metastasis from cancers of upper aero-digestive tract detected on FDG PET/CT: a series of 4 cases. Cancer Imaging (2014) 0.75

A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India. Indian J Nucl Med (2013) 0.75

Role of SPECT/CT, versus traditional practices, in individualizing treatment of thyroid carcinoma. J Nucl Med (2012) 0.75

18F-FDG uptake in small bowel intussusception in a patient of Langerhans cell histiocytosis and its resolution following successful conservative medical management. Hell J Nucl Med (2011) 0.75

The added clinical value of 18F-FDG PET/CT in evaluating intratracheal recurrence of differentiated thyroid carcinoma: implications for planning surgery, assessing its completeness, and planning radioiodine therapy. J Nucl Med Technol (2013) 0.75

Short course of oral lithium therapy as an adjunct in patients with thyrotoxicosis who failed initial radioiodine therapy: should this be worthwhile to consider in the absence of contraindications? Nucl Med Commun (2017) 0.75

(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites. World J Nucl Med (2017) 0.75

Thymus uptake of (131) I in patients with differentiated thyroid carcinoma: Three different case scenarios and patterns of uptake and the importance of its recognition in thyroid cancer practice. J Cancer Res Ther (2015) 0.75

Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables. Nucl Med Commun (2014) 0.75

Unusual solitary splenic metastasis from pyriform fossa carcinoma detected by FDG-PET. Indian J Cancer (2016) 0.75

Response to: Oral lithium as an adjunctive therapy during radioiodine treatment for hyperthyroidism. Nucl Med Commun (2017) 0.75

F-18 FDG PET findings in a port site recurrence after laparoscopic radical nephrectomy in a patient with renal cell carcinoma. Clin Nucl Med (2008) 0.75